You can view Dr Vasileios Angelis’ PubMed in full here.
Selected Publications
The Management of ER-Low, HER2-Negative Breast Cancer in the United Kingdom: A Survey of Current Clinical Practice. Oncology and Therapy. Sit K, Berner A, McCahill C, Atkinson S, Phillips M, Hawkesford K, Angelis V, Hall P. 2025;13. doi:10.1007/s40487-025-00388-6.
Circulating tumour DNA detection in stage I HER2-positive and triple-negative breast cancer (SAFE-DE). Annals of Oncology. Medford H, Mohammed et al.
Discrepancies in the assessment of oestrogen and progesterone receptor status using immunohistochemistry and OncotypeDX; reclassification to triple-negative breast cancer and implications for treatment. Irakleidis F, Thorat M, Angelis V. The Breast. 2025;80:104249.
Ethnic disparities in pathological complete response and immune-related adverse events with neoadjuvant pembrolizumab in early triple-negative breast cancer. Cheney Lowe H, Yau T, Rahman F, Schmid P, Phillips M, Angelis V. Annals of Oncology. 2025.
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries. Cortellini A, Dettorre GM, Dafni U, Aguilar-Company J, Castello-Branco L, Lambertini M, Gennatas S, Angelis V, et al. Journal for ImmunoTherapy of Cancer. 2022;10:e005732. doi:10.1136/jitc-2022-005732.
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors. Stavraka C, et al. Clinical Colorectal Cancer. 2021;20(4). doi:10.1016/j.clcc.2021.09.009.
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, Senthivel N, Asavisanu K, Obeid M, Tripodaki ES, Angelis V, Fleming E, Goode EF, John S, Rosen SD, Allen M, Stanway S, Lyon AR, Ring A. Breast Cancer Research and Treatment. 2021;188(1):149–163. doi:10.1007/s10549-021-06192-w.
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lee LYW, et al. The Lancet Oncology. 2020;21(10):1309–1316. doi:10.1016/S1470-2045(20)30442-3.
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lee LYW, Cazier JB, Starkey T, et al. The Lancet. 2020. doi:10.1016/S0140-6736(20)31173-9.
Defining the true impact of COVID-19 in the at-risk population of cancer patients. Angelis V, Tippu Z, Fribbens C, Gennatas S.  European Journal of Cancer. 2020;136:99–106.
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Angelis V, Johnston SRD. Drugs. 2019;79(17):1849–1866. doi:10.1007/s40265-019-01208-8.
Peri-operative therapy for operable gastroesophageal adenocarcinoma: Past, present and future. Angelis V, Cunningham D, Riddick F, Smyth EC. Annals of Oncology. 2018;29(6).
VHL-dependent regulation of a beta-dystroglycan glycoform and glycogene expression in renal cancer. Angelis V, Craven RA, Peng J, Harnden P, Schaffer L, Hernandez GE, Head SR, Maher ER, Tonge R, Selby PJ, Banks RE. International Journal of Oncology. 2013;43(5):1368–1376.
Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Angelis V, Craven RA, Peng J, Harnden P, Cairns DA, Maher ER, Tonge R, Selby PJ, Banks RE. Proteomics. 2009;9(8):2118–2130.
